You are now leaving ironwoodpharma.com. This link will take you to
a website to which our privacy policy does not apply. You are solely
responsible for your interactions with that website.

Linaclotide Delayed Release-1

Completed Phase II Clinical Development

Area of focus:

Irritable Bowel Syndrome with Constipation (IBS-C)
While estimates vary, as many as 13 million adults in the U.S. may suffer from IBS-C,1 a functional gastrointestinal disorder in which individuals experience hallmark symptoms of abdominal pain and infrequent bowel movements (less than three times per week). Abdominal pain is one of the predominant symptoms associated with IBS, with greater than 75% of patients with IBS-C reporting continuous or frequent abdominal pain, according to the International Foundation for Functional Gastrointestinal Disorders. Learn more about IBS-C »

Our candidate:

Linaclotide delayed release-1 (DR1) is an investigational medicine being studied to determine whether it can provide delivery of linaclotide to the distal small intestine and colon, and whether this may provide improved abdominal pain relief in patients with IBS-C while maintaining an effect on fluid secretion. DR1 is being co-developed by Ironwood Pharmaceuticals and Allergan plc, and has completed a Phase IIb trial in IBS-C.

« Back to Pipeline


1) Saito, Y., “The epidemiology of irritable bowel syndrome in North America: a systemic review,” Am. J. of Gastroenterology, 2002